{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-24-000138","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.759231+00:00","generated_at":"2026-05-30T13:41:03.632480+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Nurix appoints drug commercialization veteran Anil Kapur to board of directors","bullets":["Appointed Anil Kapur as Class I director effective Oct 15, 2024, with term expiring at 2027 annual meeting.","Mr. Kapur brings 25+ years of pharma exec experience, including launching Imbruvica and Darzalex.","Received initial stock option for 50,000 shares vesting monthly over 3 years, plus annual equity awards.","Appointment aims to support plan to advance NX-5948 into pivotal testing in 2025 and prepare for commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-24-000138","json":"https://secwatch.observer/filing/0001549595-24-000138.json","markdown":"https://secwatch.observer/filing/0001549595-24-000138.md","text":"https://secwatch.observer/filing/0001549595-24-000138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/0001549595-24-000138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/nrix-20241015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:41:03.632480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b95dfb8777","claim":"Anil Kapur was appointed as Director at Nurix Therapeutics, Inc..","evidence_excerpt":"On October 15, 2024, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Anil Kapur to serve as a director of the Company and as a member of the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/0001549595-24-000138-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}